ST1326

ST1326 (also known as Teglicar) is a potent, reversible small molecule inhibitor of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme responsible for the transport of long-chain fatty acids into the mitochondria for beta-oxidation. By blocking CPT1 activity, ST1326 suppresses mitochondrial fatty acid oxidation (FAO), leading to reduced ATP production and metabolic reprogramming. This mechanism has been explored in various therapeutic contexts, including hematologic malignancies such as acute myeloid leukemia (AML), where malignant cells often exhibit a high dependency on FAO for survival and chemoresistance. Additionally, emerging research indicates that ST1326 may modulate inflammatory signaling pathways, such as the JAK/STAT cascade, in the intestinal epithelium, suggesting potential applications in the treatment of Crohn's disease and other inflammatory bowel diseases. The compound was originally developed by Sigma-Tau.

Other names

Teglicar(R)-N-(tetradecylcarbamoyl)-aminocarnitine